Skip to main content


Generic name: mobocertinib
Brand name: Exkivity
Dosage form: oral capsule
Drug class: EGFR inhibitors

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 4, 2023.

What is mobocertinib?

Mobocertinib is a type of drug called a kinase inhibitor, which is used to treat a rare type of non-small cell lung cancer (NSCLC).

Mobocertinib is used to treat NSCLC caused by a specific type of gene mutation called an epidermal growth factor receptor (EGFR) exon 20 insertion mutation. Only about 2000 to 4000 people are diagnosed with this type of cancer in the US each year.

EGFR is a protein that helps cells to grow and divide. When an exon 20 insertion mutation occurs, it drives cells to grow and divide abnormally, causing an EGFR-positive cancer.

Mobocertinib works by binding to and blocking EGFR exon 20 insertion mutations, which helps to slow the growth of cancer cells.

Mobocertinib was granted accelerated approval by the US Food and Drug Administration (FDA) in 2021. It is used with the Oncomine Dx Target Test, which identifies patients with exon 20 insertion mutations.

What is mobocertinib used for?

Mobocertinib is a prescription medicine used to treat adults with NSCLC:

Your healthcare provider will perform a test to make sure that mobocertinib is right for you.

It is not known if mobocertinib is safe and effective in children.

Important information

Mobocertinib may cause serious side effects, including:

See "What are the side effects of mobocertinib?" below for more information about side effects.

What should I tell my doctor before taking mobocertinib?

Before taking mobocertinib, tell your healthcare provider about all of your medical conditions, including if you:

How should I take mobocertinib?

What happens if I miss a dose?

If you miss a dose of mobocertinib, and it has been more than 6 hours, skip the dose and take your next dose at your regularly scheduled time the next day.

If you vomit a dose of mobocertinib, do not take an extra dose. Take your next dose at your regularly scheduled time the next day.

What should I avoid while taking mobocertinib?

Avoid eating grapefruit or drinking grapefruit juice during treatment with mobocertinib. Grapefruit may increase the amount of mobocertinib in your blood.

Dosing information

The recommended dose of mobocertinib is 160 mg taken orally once a day. Mobocertinib can be taken with or without food.

See full prescribing information for further details about mobocertinib dosing.

What are the side effects of mobocertinib?

Mobocertinib may cause serious side effects, including:

The most common side effects of mobocertinib include:

Mobocertinib may affect fertility in females and males, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of mobocertinib.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider if you take medicines for heart problems.

Mobocertinib and other medicines may affect each other causing serious side effects.

Pregnancy and breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant. Mobocertinib can harm your unborn baby.

Females who are able to become pregnant:

Males who have female partners who are able to become pregnant:

Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if mobocertinib passes into your breast milk. Do not breastfeed during treatment and for 1 week after your last dose of mobocertinib.


Keep mobocertinib and all medicines out of the reach of children.

What are the ingredients in mobocertinib?

Active ingredient: mobocertinib

Inactive ingredients: None

Capsule shells: gelatin and titanium dioxide. The printing ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide, potassium hydroxide, and purified water.

Mobocertinib is distributed under the brand name Exkivity by Takeda Pharmaceuticals America, Inc., Lexington, MA 02421.

Popular FAQ

On October 2, 2023 Takeda Pharmaceuticals announced the voluntary withdrawal of Exkivity from the U.S and global markets. Exkivity did not meet the primary endpoint of the Phase 3 EXCLAIM-2 confirmatory trial and did not meet the requirements of the Accelerated Approval granted by the FDA for the treatment of NSCLC.

In clinical studies, 32 of 114 patients (28%) with NSCLC had a partial response to Exkivity treatment. In these patients, the response to treatment lasted for about 17.5 months. Close to 59% of patients who responded had a response that lasted at least 6 months Continue reading

More about mobocertinib

Patient resources

Other brands


Professional resources

Other brands


Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.